The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis

It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 19; no. 1; pp. 511 - 9
Main Authors Zhang, Zeyu, Zhou, Yufan, Yang, Jiajin, Hu, Kuan, Huang, Yun
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 29.05.2019
BioMed Central
BMC
Subjects
Analysis
Antigens
Antiretroviral agents
Antiretroviral drugs
Cancer
Cancer research
Carcinoma
Care and treatment
Chronic hepatitis B
Clinical trials
Encephalopathy
Entecavir
Hepatitis
Hepatitis B
Hepatitis B virus
Hepatocellular carcinoma
Immunosuppressive agents
Infections
Liver
Liver cancer
Liver diseases
Medical research
Meta-analysis
Patient outcomes
Patients
Practice guidelines (Medicine)
Ratios
Risk factors
Studies
Surgery
Systematic review
Tenofovir
Transplantation
Tenofovir
Hepatocellular carcinoma
Chronic hepatitis B
Entecavir
Meta-analysis
Online AccessGet full text

Cover

Abstract It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
AbstractList It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes.BACKGROUNDIt has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes.Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis.METHODSDatabases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis.Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups.RESULTSSeven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups.There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.CONCLUSIONThere is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Methods Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Results Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. Conclusion There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Methods Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Results Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. Conclusion There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future. Keywords: Entecavir, Tenofovir, Chronic hepatitis B, Hepatocellular carcinoma, Meta-analysis
Abstract Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Methods Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Results Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. Conclusion There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.
ArticleNumber 511
Audience Academic
Author Hu, Kuan
Yang, Jiajin
Zhou, Yufan
Huang, Yun
Zhang, Zeyu
Author_xml – sequence: 1
  givenname: Zeyu
  surname: Zhang
  fullname: Zhang, Zeyu
– sequence: 2
  givenname: Yufan
  surname: Zhou
  fullname: Zhou, Yufan
– sequence: 3
  givenname: Jiajin
  surname: Yang
  fullname: Yang, Jiajin
– sequence: 4
  givenname: Kuan
  surname: Hu
  fullname: Hu, Kuan
– sequence: 5
  givenname: Yun
  orcidid: 0000-0001-8517-0516
  surname: Huang
  fullname: Huang, Yun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31142283$$D View this record in MEDLINE/PubMed
BookMark eNp1kl1v0zAYhSM0xD7gB3CDIiEhuMjwV2J7F0ijbLTSJCQoiDvLdd60rlK7xE7F_j3OuqFmAvki1uvnnNhH5zQ7ct5Blr3E6BxjUb0PmAhRFgjLouS0LOST7AQzjgvCED862B9npyGsEcJcIPEsO6YYM0IEPcl-zleQQ9OAiXYHDkLIfZPPP13nO-hCH_Kr-Y_cu9w6Y2twBobj6WSSBvlk-jHf6mjBxXCR63wDUefa6fY22PA8e9roNsCL--9Z9v36aj6ZFjdfPs8mlzeFqSSOBa4lAi41KfHCECkEEyjdDcBUVSkxZbBAFGHEtVlQTmlZ0YoyudCsNtIAoWfZbO9be71W285udHervLbqbuC7pdJdtKYFBSI5UwGskpLRGjRtGEJM1yAkQndeH_Ze236xgdqkh3W6HZmOT5xdqaXfqapkJKWbDN7eG3T-Vw8hqo0NBtpWO_B9UIRQwniKvkro60fo2vddCm-gGCW8lOyAWur0AOsan_5rBlN1WUrEUUk4T9T5P6i0athYkzrT2DQfCd6NBImJ8DsudR-Cmn37OmbfHLAr0G1cBd_20XoXxuCrw_T-xvZQtgTwPWA6H0IHjTI26sEnXde2CiM11Frta61SrdVQayWTEj9SPpj_X_MH1NDyoQ
CitedBy_id crossref_primary_10_3346_jkms_2021_36_e89
crossref_primary_10_1016_j_jhep_2021_09_017
crossref_primary_10_1038_s41575_019_0257_0
crossref_primary_10_4254_wjh_v15_i2_237
crossref_primary_10_1111_apt_16197
crossref_primary_10_57264_cer_2023_0090
crossref_primary_10_1111_apt_16116
crossref_primary_10_1111_apt_16356
crossref_primary_10_1016_j_jhep_2020_06_011
crossref_primary_10_1111_jgh_15078
crossref_primary_10_1016_j_jhep_2022_12_007
crossref_primary_10_1111_jgh_15036
crossref_primary_10_1016_j_cld_2023_05_005
crossref_primary_10_14309_ajg_0000000000001157
crossref_primary_10_3389_fmed_2021_637126
crossref_primary_10_3390_cancers14112617
crossref_primary_10_1016_j_cgh_2021_03_035
crossref_primary_10_1007_s11901_022_00588_y
crossref_primary_10_1111_apt_16786
crossref_primary_10_1002_hep_31438
crossref_primary_10_1016_j_cld_2022_08_001
crossref_primary_10_1186_s12885_022_09413_7
crossref_primary_10_1111_jgh_15783
crossref_primary_10_1007_s11901_019_00502_z
crossref_primary_10_3390_diagnostics13203212
crossref_primary_10_1016_j_clinre_2021_101722
crossref_primary_10_1007_s12072_019_10005_0
crossref_primary_10_1016_S2468_1253_20_30249_1
crossref_primary_10_1001_jamanetworkopen_2022_19407
crossref_primary_10_3390_ph14050417
crossref_primary_10_3390_jcm13226770
crossref_primary_10_1111_liv_14367
crossref_primary_10_1177_2040206620921331
crossref_primary_10_1186_s12876_021_01711_x
crossref_primary_10_4103_sjg_sjg_527_21
crossref_primary_10_1111_jvh_13553
crossref_primary_10_1002_hep_31289
crossref_primary_10_1016_j_jhep_2019_06_013
crossref_primary_10_18632_aging_202573
crossref_primary_10_1159_000507253
crossref_primary_10_2147_JHC_S331779
crossref_primary_10_1186_s13045_024_01528_7
crossref_primary_10_1016_j_jhep_2024_08_028
crossref_primary_10_14309_ctg_0000000000000236
crossref_primary_10_1038_s41598_020_70433_z
crossref_primary_10_1016_j_gendis_2019_12_014
crossref_primary_10_1097_MEG_0000000000001733
crossref_primary_10_3390_diagnostics12092085
crossref_primary_10_1159_000518940
crossref_primary_10_1371_journal_pone_0224773
Cites_doi 10.1002/jcph.409
10.3389/fimmu.2017.00119
10.1053/gast.2003.50013
10.1111/hepr.13194
10.1007/s12072-015-9609-1
10.1002/hep.29501
10.1002/hep.26180
10.1111/apt.12344
10.1111/jvh.12332_15
10.1002/hep.25869
10.1016/j.cgh.2012.10.003
10.1007/s12664-015-0576-1
10.1016/j.hepres.2005.02.006
10.4103/sjg.SJG_49_18
10.1590/S0037-86822008000600001
10.1016/j.jhep.2009.07.009
10.1016/j.cld.2016.07.002
10.1016/S0016-5085(11)63860-2
10.1016/j.cmi.2015.05.035
10.1053/j.gastro.2011.12.061
10.1007/s12072-018-9852-3
10.4318/tjg.2012.0380
10.1016/S0140-6736(03)14964-1
10.1016/j.jhep.2012.02.033
10.1128/AAC.42.12.3209
10.1111/hepr.12743
10.1016/j.antiviral.2013.08.020
10.1016/j.cld.2013.05.001
10.1002/hep.25937
10.3748/wjg.14.4300
10.1001/jama.2018.3795
10.1016/j.jfma.2016.08.006
10.1371/journal.pone.0102761
10.1056/NEJMoa1105243
10.1136/gutjnl-2016-312653
10.1111/jvh.12971
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12885-019-5735-9
DatabaseName CrossRef
PubMed
Science in Context
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Acceso a contenido Full Text - Doaj
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 9
ExternalDocumentID oai_doaj_org_article_e814238e469943dea3f4004ade8900e2
PMC6542001
A590705277
31142283
10_1186_s12885_019_5735_9
Genre Journal Article
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
NPM
PMFND
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c691t-1d90e79a251bc2988480142eec6659134eb030107acb37335636349ba4dc9ce23
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Aug 27 01:32:12 EDT 2025
Thu Aug 21 13:59:42 EDT 2025
Fri Jul 11 11:48:55 EDT 2025
Fri Jul 25 03:20:07 EDT 2025
Tue Jun 17 21:06:48 EDT 2025
Tue Jun 10 20:42:25 EDT 2025
Fri Jun 27 04:52:06 EDT 2025
Thu May 22 20:58:48 EDT 2025
Thu Jan 02 23:02:24 EST 2025
Tue Jul 01 03:06:15 EDT 2025
Thu Apr 24 22:57:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Tenofovir
Hepatocellular carcinoma
Chronic hepatitis B
Entecavir
Meta-analysis
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c691t-1d90e79a251bc2988480142eec6659134eb030107acb37335636349ba4dc9ce23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ORCID 0000-0001-8517-0516
OpenAccessLink https://doaj.org/article/e814238e469943dea3f4004ade8900e2
PMID 31142283
PQID 2243275946
PQPubID 44074
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_e814238e469943dea3f4004ade8900e2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6542001
proquest_miscellaneous_2232474226
proquest_journals_2243275946
gale_infotracmisc_A590705277
gale_infotracacademiconefile_A590705277
gale_incontextgauss_ISR_A590705277
gale_healthsolutions_A590705277
pubmed_primary_31142283
crossref_citationtrail_10_1186_s12885_019_5735_9
crossref_primary_10_1186_s12885_019_5735_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-05-29
PublicationDateYYYYMMDD 2019-05-29
PublicationDate_xml – month: 05
  year: 2019
  text: 2019-05-29
  day: 29
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References H Janssen (5735_CR31) 2014; 21
LH Lannoy (5735_CR13) 2008; 41
YM Kim (5735_CR18) 2018; 24
IH Song (5735_CR28) 2018; 2
B Li (5735_CR27) 2015; 1
L Tang (5735_CR8) 2018; 319
T Asselah (5735_CR1) 2013; 17
P Yuan (5735_CR26) 2016; 2016
K Murata (5735_CR29) 2016; 67
Ching-Lung Lai (5735_CR6) 2013; 57
SK Goyal (5735_CR15) 2015; 34
M Syedbasha (5735_CR30) 2017; 8
5735_CR16
DA B (5735_CR36) 2012; 23
T Sriprayoon (5735_CR37) 2017; 47
AOK Ovunc (5735_CR38) 2011; 140
MC Tsai (5735_CR39) 2016; 22
S Kubo (5735_CR22) 2000; 88
JM Llovet (5735_CR5) 2003; 362
T Hosaka (5735_CR7) 2013; 58
A Matsumoto (5735_CR24) 2005; 32
JC Wu (5735_CR21) 2009; 51
HB El-Serag (5735_CR2) 2012; 142
EV Genovesi (5735_CR34) 1998; 42
CY Peng (5735_CR32) 2012; 57
JH Yu (5735_CR20) 2018; 48
M Srivastava (5735_CR3) 2013; 100
MS Cohen (5735_CR12) 2011; 365
JL Dienstag (5735_CR23) 2003; 124
DN Standring (5735_CR35) 2001; 12
S Zuo (5735_CR9) 2015; 55
AK Singal (5735_CR10) 2013; 38
M Tsai (5735_CR17) 2017; 116
BK Luvisa (5735_CR33) 2016; 20
P Sun (5735_CR25) 2014; 9
S Köklü (5735_CR14) 2013; 11
M Sherman (5735_CR11) 2012; 56
AI Gomaa (5735_CR4) 2008; 14
BG Kim (5735_CR19) 2018; 25
References_xml – volume: 55
  start-page: 288
  issue: 3
  year: 2015
  ident: 5735_CR9
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.409
– volume: 8
  start-page: 119
  year: 2017
  ident: 5735_CR30
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00119
– volume: 124
  start-page: 105
  issue: 1
  year: 2003
  ident: 5735_CR23
  publication-title: Gastroenterology.
  doi: 10.1053/gast.2003.50013
– volume: 48
  start-page: 862
  issue: 11
  year: 2018
  ident: 5735_CR20
  publication-title: Hepatol Res
  doi: 10.1111/hepr.13194
– volume: 1
  start-page: S42
  issue: 9
  year: 2015
  ident: 5735_CR27
  publication-title: Hepatol Int
  doi: 10.1007/s12072-015-9609-1
– ident: 5735_CR16
  doi: 10.1002/hep.29501
– volume: 58
  start-page: 98
  issue: 1
  year: 2013
  ident: 5735_CR7
  publication-title: Hepatology.
  doi: 10.1002/hep.26180
– volume: 38
  start-page: 98
  issue: 2
  year: 2013
  ident: 5735_CR10
  publication-title: Aliment Pharm Ther
  doi: 10.1111/apt.12344
– volume: 88
  start-page: 1016
  issue: 5
  year: 2000
  ident: 5735_CR22
  publication-title: Cancer-Am Cancer Soc
– volume: 21
  start-page: 12
  issue: s2
  year: 2014
  ident: 5735_CR31
  publication-title: J Viral Hepatitis.
  doi: 10.1111/jvh.12332_15
– volume: 56
  start-page: 793
  issue: 3
  year: 2012
  ident: 5735_CR11
  publication-title: Hepatology.
  doi: 10.1002/hep.25869
– volume: 11
  start-page: 88
  issue: 1
  year: 2013
  ident: 5735_CR14
  publication-title: Clin Gastroenterol H
  doi: 10.1016/j.cgh.2012.10.003
– volume: 34
  start-page: 286
  issue: 4
  year: 2015
  ident: 5735_CR15
  publication-title: Indian J Gastroenterol
  doi: 10.1007/s12664-015-0576-1
– volume: 32
  start-page: 173
  issue: 3
  year: 2005
  ident: 5735_CR24
  publication-title: Hepatol Res
  doi: 10.1016/j.hepres.2005.02.006
– volume: 24
  start-page: 326
  issue: 6
  year: 2018
  ident: 5735_CR18
  publication-title: Saudi J Gastroenterol
  doi: 10.4103/sjg.SJG_49_18
– volume: 41
  start-page: 549
  issue: 6
  year: 2008
  ident: 5735_CR13
  publication-title: Rev Soc Bras Med Trop
  doi: 10.1590/S0037-86822008000600001
– volume: 51
  start-page: 890
  issue: 5
  year: 2009
  ident: 5735_CR21
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.07.009
– volume: 20
  start-page: 681
  issue: 4
  year: 2016
  ident: 5735_CR33
  publication-title: Clin Liver Dis.
  doi: 10.1016/j.cld.2016.07.002
– volume: 140
  start-page: 930
  issue: 5
  year: 2011
  ident: 5735_CR38
  publication-title: Gastroenterology.
  doi: 10.1016/S0016-5085(11)63860-2
– volume: 22
  start-page: 91
  issue: 1
  year: 2016
  ident: 5735_CR39
  publication-title: Clin Microbiol Infec
  doi: 10.1016/j.cmi.2015.05.035
– volume: 142
  start-page: 1264
  issue: 6
  year: 2012
  ident: 5735_CR2
  publication-title: Gastroenterology.
  doi: 10.1053/j.gastro.2011.12.061
– volume: 2
  start-page: S334
  issue: 12
  year: 2018
  ident: 5735_CR28
  publication-title: Hepatol Int
  doi: 10.1007/s12072-018-9852-3
– volume: 23
  start-page: 247
  issue: 3
  year: 2012
  ident: 5735_CR36
  publication-title: Turk J Gastroenterol
  doi: 10.4318/tjg.2012.0380
– volume: 362
  start-page: 1907
  issue: 9399
  year: 2003
  ident: 5735_CR5
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(03)14964-1
– volume: 57
  start-page: 442
  issue: 2
  year: 2012
  ident: 5735_CR32
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.02.033
– volume: 42
  start-page: 3209
  issue: 12
  year: 1998
  ident: 5735_CR34
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.42.12.3209
– volume: 47
  start-page: E161
  issue: 3
  year: 2017
  ident: 5735_CR37
  publication-title: Hepatol Res
  doi: 10.1111/hepr.12743
– volume: 100
  start-page: 300
  issue: 2
  year: 2013
  ident: 5735_CR3
  publication-title: Antivir Res
  doi: 10.1016/j.antiviral.2013.08.020
– volume: 17
  start-page: 445
  issue: 3
  year: 2013
  ident: 5735_CR1
  publication-title: Clin Liver Dis
  doi: 10.1016/j.cld.2013.05.001
– volume: 57
  start-page: 399
  issue: 1
  year: 2013
  ident: 5735_CR6
  publication-title: Hepatology
  doi: 10.1002/hep.25937
– volume: 14
  start-page: 4300
  issue: 27
  year: 2008
  ident: 5735_CR4
  publication-title: World J Gastroentero
  doi: 10.3748/wjg.14.4300
– volume: 319
  start-page: 1802
  issue: 17
  year: 2018
  ident: 5735_CR8
  publication-title: JAMA.
  doi: 10.1001/jama.2018.3795
– volume: 2016
  start-page: 5234969
  year: 2016
  ident: 5735_CR26
  publication-title: Can J Gastroenterol
– volume: 116
  start-page: 512
  issue: 7
  year: 2017
  ident: 5735_CR17
  publication-title: J Formos Med Assoc
  doi: 10.1016/j.jfma.2016.08.006
– volume: 9
  issue: 7
  year: 2014
  ident: 5735_CR25
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0102761
– volume: 365
  start-page: 493
  issue: 6
  year: 2011
  ident: 5735_CR12
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1105243
– volume: 67
  start-page: 362
  issue: 2
  year: 2016
  ident: 5735_CR29
  publication-title: Gut.
  doi: 10.1136/gutjnl-2016-312653
– volume: 25
  start-page: 1565
  issue: 12
  year: 2018
  ident: 5735_CR19
  publication-title: J Viral Hepatitis
  doi: 10.1111/jvh.12971
– volume: 12
  start-page: 119
  issue: Suppl 1
  year: 2001
  ident: 5735_CR35
  publication-title: Antivir Chem Chemother
SSID ssj0017808
Score 2.4826012
Snippet It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus...
Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus...
Abstract Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 511
SubjectTerms Analysis
Antigens
Antiretroviral agents
Antiretroviral drugs
Cancer
Cancer research
Carcinoma
Care and treatment
Chronic hepatitis B
Clinical trials
Encephalopathy
Entecavir
Hepatitis
Hepatitis B
Hepatitis B virus
Hepatocellular carcinoma
Immunosuppressive agents
Infections
Liver
Liver cancer
Liver diseases
Medical research
Meta-analysis
Patient outcomes
Patients
Practice guidelines (Medicine)
Ratios
Risk factors
Studies
Surgery
Systematic review
Tenofovir
Transplantation
SummonAdditionalLinks – databaseName: Acceso a contenido Full Text - Doaj
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_Eirp91V40iCELZtvn2tjvuMArrQWdlbiFJ36igrdiZ_9-8NDNMEfTitXmFzi_vc_Lye4S8dKZqfSNZyQXwkoNhpcFihXvPueFhDamb8OqDXFzz9yuxOhj1hT1hIz3wCNwZ6DpGfA2xjDOcteDYGtXOtaBNVUHyvjHm7YqpfH6gdKXzGWat5dkQvbDGJjVTCsVEaSZRKJH1_-mSD2LStF_yIADN75DbOXOk5-MXH5Mb0N0lN6_y2fg9soo7Tsf2jOzBaL-my7dzip0X24FeLj_TvqP453oaJIrLi9ksPqCzxQXNDKvDG-roD9g46jJfyX1yPb9czhZlnptQBmnqTVm3pgJlXExdfGiM1okipgEIUgo8aQePhVClXPBMMSYkk4wb73gbTICGPSBHXd_BI0Jj3W1EFQQmhpwxp5va19B6DY2vhYaCVDscbcik4jjb4rtNxYWWdoTeRugtQm9NQV7vX_k5Mmr8TfgCN2cviGTY6UFUEZtVxP5LRQryDLfWjjdL9yZtz4WJDk80ShXkRZJAQowOO26-uO0w2HefPk6EXmWhdR9_Y3D5AkNECjm0JpKnE8losWG6vNMxmz3GYGMqxRolDJcFeb5fxjexC66DfosyMf1VePe5IA9Hldwjw9KlaM0KoibKOoFuutJ9-5r4xHFmWbSZx_8D6xNyq0Ezq0TZmFNytPm1hScxbdv4p8lCfwM6wDh5
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aQXwRv7taNYogCEt38x1fpD17nEJ90KvcW0iyuSrobu3e_f9msrm1i9DXZAK7k8xkJvnlNwi9sbpqHBG0ZDywkgVNSw3JCnOOMc38OiQ04ekXsThjn1d8lQ_c-gyr3PnE5KibzsMZ-WHcaiiRXDPx4eJPCVWj4HY1l9C4iW4BdRlAuuRqTLhqqSqVbzJrJQ776IsVQNV0ySXlpZ7sRYmy_3_HfGVnmqImr2xD83vobo4f8dEw4ffRjdA-QLdP8w35Q7SK844HkEb2Y7hb4-XHOQb8xbbHJ8vvuGsxHLGncqLQvZjNYgOeLY5x5lnt32OLf4eNxTazljxCZ_OT5WxR5uoJpRe63pR1o6sgtY0BjPNEK5WIYkgIXggO9-3BQTpUSesdlZRyQQVl2lnWeO0DoY_RXtu1YR_hmH1rXnkO4SGj1CpSuzo0TgXiaq5CgaqdHo3P1OJQ4eKXSSmGEmZQvYmqN6B6owv0bhxyMfBqXCd8DJMzCgIldmroLs9NtjATVPw7qkLM9zWjTbB0Df7JNkHpqgqkQC9has3wvnQ0bHPEdXR7nEhZoNdJAmgxWsDdnNtt35tP375OhN5moXUX_9Hb_IwhagqYtCaSBxPJaLd-2r1bYyb7jd78W-UFejV2w0jAwrWh24JMDIIlvIAu0JNhSY6aoelptKIFkpPFOlHdtKf9-SOxikPlsmgzT6__rGfoDgEDqnhJ9AHa21xuw_MYlm3ci2R7fwE73jCk
  priority: 102
  providerName: ProQuest
Title The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/31142283
https://www.proquest.com/docview/2243275946
https://www.proquest.com/docview/2232474226
https://pubmed.ncbi.nlm.nih.gov/PMC6542001
https://doaj.org/article/e814238e469943dea3f4004ade8900e2
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9NAEF_uA8QX8ducZ11FEIRosh_ZXUHkWluq0ENqK8WXZZNsT-Eu0aYF_e_d2WzrBQ_xpQ_ZSSGT-c3OZGZ_g9Azo5IyJxmNGbcsZlbRWEGywvKcMcWKpfXdhJPTbDxnHxZ8sYe2462CApsrUzuYJzVfnb_8-ePXWwf4Nx7wMnvVOB8roQVNxVxQHqt9dOg2JgE4nbA_RQUh_YC61PljKCqIUOS88i8625Rn8__bZ1_atLoNlZd2qNFNdCOElviktYVbaM9Wt9G1SSie30ELZxK47d8ILg7XSzx7N8LQmrFp8HD2GdcVhq_vftIoLI8HA3cBD8Z9HChYm9fY4Au7NtgEQpO7aD4azgbjOAxWiItMpes4LVVihTIutskLoqT0HDLE2iLLOJTibQ6ZUiJMkVNBKc9oRpnKDSsLVVhC76GDqq7sA4RdYq54UnCIHBmlRpI0T22ZS0vylEsboWSrR10E1nEYfnGuffYhM92qXjvVa1C9VhF6sbvle0u58S_hPrycnSCwZfsL9epMB_BpK93TUWlZphSjpTV0Ca7LlFaqJLEkQo_h1er26OkO8_qEK-cROREiQk-9BDBmVNCSc2Y2TaPff5p2hJ4HoWXtnrEw4YSD0xSQbHUkjzuSDtJFd3lrY3qLCO1iLUoEVyyL0JPdMtwJbXKVrTcg4-JjAYejI3S_NcmdZqg_NS1phETHWDuq665U3756wnEYaubwc_Q_SniIrhOAUcJjoo7RwXq1sY9c3LbOe2hfLEQPHfaHpx-nPf_1o-cR6n6n_S-_AQo7PA4
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTgJeEN8EBjMIhIQULfFHYiMhtHatWrZWaHRT34zjuAMJkrG0QvxT_I34EjcsQtrbXuOzlJzvw5e7-x1Cr7SM8owkNGTcspBZSUMJwQrLMsYkM0tbVxNOZ8n4hH1c8MUW-rPphYGyyo1NrA11Xhr4R77nXA0lKZcs-XD-M4SpUZBd3YzQaMTi0P7-5UK26v3kwJ3va0JGw_lgHPqpAqFJZLwK41xGNpXaOfbMEClEDaBCrDVJwiEPbTMIE6JUm4ymlPKEJpTJTLPcSGMB6MCZ_G1GXSjTQ9v94ezTcZu3SEUkfO40Fsle5ay_gOI4GfKU8lB2vF89JOB_V3DJF3brNC85vtEddNvfWPF-I2J30ZYt7qEbU5-Tv48WTtJwUxbiLScul3h-MMJQ8bGu8HB-issCw0_9eoApLI8HA_cAD8Z97JFdq3dY4x92pbH2OCkP0Mm1cPYh6hVlYR8j7OJ9ySPD4ULKKNWCxFls80xYksVc2ABFGz4q48HMYabGd1UHNSJRDeuVY70C1isZoLftlvMGyeMq4j4cTksIINz1g_LiTHmdVla4r6PCskRKRnOr6RIsos6tkFFkSYB24WhV09HamhK1z6UztJykaYBe1hQAxFFApc-ZXleVmnw-7hC98UTL0n2j0b5xwnEKsLs6lDsdSmcpTHd5I2PKW6pK_dOrAL1ol2EnVN8VtlwDjbt2p9BzHaBHjUi2nKF1M7agAUo7wtphXXel-Pa1xjGHWWlOZ55c_Vq76OZ4Pj1SR5PZ4VN0i4AyRTwkcgf1Vhdr-8xdClfZc6-JGH25buX_CxKTbL0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effectiveness+of+TDF+versus+ETV+on+incidence+of+HCC+in+CHB+patients%3A+a+meta+analysis&rft.jtitle=BMC+cancer&rft.au=Zhang%2C+Zeyu&rft.au=Zhou%2C+Yufan&rft.au=Yang%2C+Jiajin&rft.au=Hu%2C+Kuan&rft.date=2019-05-29&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-019-5735-9&rft.externalDBID=ISR&rft.externalDocID=A590705277
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon